Patrice Hugo, Ph.D. | February 12, 2019

Key Central Laboratory Capabilities to Enable Successful Immuno-Oncology Clinical Development

Trends and recommendations in laboratory selection
This presentation provides the laboratory and operational requirements of immuno-oncology trials, and explores trends in I-O drug development and biomarker usage. Q2 Solutions presented at the Immuno-Oncology 360° 2019 conference as part of a plenary session.

Q2 Solutions has a unique role in immuno-oncology drug development, providing clinical laboratory services and utilizing early engagement and continuous communication with partners and clients to drive higher quality results.

Download this presentation to learn more.

Patrice Hugo, PhD, Chief Scientific Officer

Related Services:
Q2 Solutions Biomarker Services

Providing tools and experience to maximize your biomarker strategy

The Power of the Central Laboratory for Immuno-Oncology Drug Development

New Opportunities for Immuno-oncology Clinical Development Programs through T cell/B cell Repertoire Profiling

Immune repertoire profiling provides better outcomes for immuno-oncology development programs

Read More